Anneliese Jameson is Senior Vice President, Clinical and Development Operations at Kyverna Therapeutics and is responsible for the Company’s Clinical Operations and Clinical Data Management functions, as well as enterprise Program Management. Anneliese is an accomplished biopharmaceutical executive with more than 25 years of experience leading global clinical development and operations organizations across oncology, cell therapy, and rare diseases.

Prior to joining Kyverna, Anneliese served as Vice President, Clinical Operations at Iovance Biotherapeutics, where she led Clinical Operations through FDA BIMO inspections supporting the approval of Amtagi®, the first individualized T-cell therapy approved for a solid tumor. She also led Clinical Operations activities supporting the company’s BLA submission and commercial launch readiness efforts. Prior to joining Iovance, Anneliese spent more than 17 years at Genentech, a member of the Roche Group, where she held positions of increasing responsibility across Clinical Operations, Program Leadership, and Competitive Intelligence, culminating as Executive Director, Global Clinical Operations. In that role, she led a global oncology portfolio spanning multiple tumor types and late-stage development programs. Earlier in her career, Anneliese held clinical research and drug development roles at Telik, Élan Pharmaceuticals, and Covance.

Anneliese holds a Master of Arts in Biological Anthropology from the University of Chicago and a Bachelor of Arts in Biological Anthropology from Hamilton College.